Benzinga | Sep 16, 2021 11:50AM EDT

BeyondSpring Presents New Plinabulin Data At ESMO Congress

* BeyondSpring Pharmaceuticals (NASDAQ:BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Congress.

* Plinabulin combined with G-CSF to prevent CIN is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30.

* The data showed that the severe neutropenia endpoint is correlated with clinically meaningful endpoints in a meta-analysis with over 7000 patients.

* Related Content: BeyondSpring Stock Is Up More than 300%: What You Need To Know?

* The meta-analysis dataset included data from 36 published world literature in various cancers and chemotherapy and the plinabulin CIN program, including 105 and 106 CIN studies (n=496).

* Correlations of exponential equations between the rate of febrile neutropenia, duration of severe neutropenia, and absolute neutrophil count nadir were statistically significant.

* In the PROTECTIVE-2 Phase 3 trial, plinabulin/pegfilgrastim combo therapy had superior efficacy in preventing severe neutropenia versus pegfilgrastim alone (68% vs. 86%).

* Patients receiving plinabulin and pegfilgrastim recovered to their pre-chemotherapy physical wellbeing levels more rapidly and experienced less deterioration.

* Price Action: BYSI stock is down 1.65% at $22.59 during the market session on the last check Thursday.

* Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)